Literature DB >> 29208625

Lowering Expectations with Niacin Treatment for CKD-MBD.

Tilman B Drüeke1, Ziad A Massy2,3.   

Abstract

Entities:  

Keywords:  Bone Diseases, Metabolic; Chronic Kidney Disease-Mineral and Bone Disorder; Probability; Renal Insufficiency, Chronic; chronic kidney disease; hyperphosphatemia; mineral metabolism; niacin; nicotinic acid; phosphate binders; phosphate transport inhibitors

Mesh:

Substances:

Year:  2017        PMID: 29208625      PMCID: PMC5753325          DOI: 10.2215/CJN.12021017

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  15 in total

Review 1.  Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.

Authors:  Sook Ryun Park; Alice Chen
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

2.  Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.

Authors:  Geoffrey A Block; David P Rosenbaum; Maria Leonsson-Zachrisson; Magnus Åstrand; Susanne Johansson; Mikael Knutsson; Anna Maria Langkilde; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 10.121

Review 3.  Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Authors:  Tamara Isakova; Joachim H Ix; Stuart M Sprague; Kalani L Raphael; Linda Fried; Jennifer J Gassman; Dominic Raj; Alfred K Cheung; John W Kusek; Michael F Flessner; Myles Wolf; Geoffrey A Block
Journal:  J Am Soc Nephrol       Date:  2015-05-12       Impact factor: 10.121

4.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

Review 5.  A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

Authors:  Wendy L St. Peter; Lori D Wazny; Eric Weinhandl; Katie E Cardone; Joanna Q Hudson
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

Review 6.  Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.

Authors:  Markus Ketteler; Geoffrey A Block; Pieter Evenepoel; Masafumi Fukagawa; Charles A Herzog; Linda McCann; Sharon M Moe; Rukshana Shroff; Marcello A Tonelli; Nigel D Toussaint; Marc G Vervloet; Mary B Leonard
Journal:  Kidney Int       Date:  2017-07       Impact factor: 10.612

Review 7.  Phosphate binders in chronic kidney disease: a systematic review of recent data.

Authors:  Jürgen Floege
Journal:  J Nephrol       Date:  2016-01-22       Impact factor: 3.902

Review 8.  Mechanism of action of niacin.

Authors:  Vaijinath S Kamanna; Moti L Kashyap
Journal:  Am J Cardiol       Date:  2008-04-17       Impact factor: 2.778

Review 9.  Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

Authors:  Aurélie Lenglet; Sophie Liabeuf; Pauline Guffroy; Albert Fournier; Michel Brazier; Ziad A Massy
Journal:  Drugs R D       Date:  2013-09

10.  Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.

Authors:  Aurélie Lenglet; Sophie Liabeuf; Najeh El Esper; Sandrine Brisset; Janette Mansour; Anne-Sophie Lemaire-Hurtel; Aurelien Mary; Michel Brazier; Said Kamel; Romuald Mentaverri; Gabriel Choukroun; Albert Fournier; Ziad A Massy
Journal:  Nephrol Dial Transplant       Date:  2017-05-01       Impact factor: 5.992

View more
  3 in total

Review 1.  Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.

Authors:  Denis Fouque; Marc Vervloet; Markus Ketteler
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

Review 2.  Npt2a as a target for treating hyperphosphatemia.

Authors:  Linto Thomas; Jessica A Dominguez Rieg; Timo Rieg
Journal:  Biochem Soc Trans       Date:  2022-02-28       Impact factor: 4.919

Review 3.  Sodium phosphate cotransporter 2a inhibitors: potential therapeutic uses.

Authors:  Jianxiang Xue; Linto Thomas; Jessica A Dominguez Rieg; Timo Rieg
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-07-18       Impact factor: 3.416

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.